Cyclic Nucleotide Phosphodiesterases, Type 5
"Cyclic Nucleotide Phosphodiesterases, Type 5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC GMP. It is found predominantly in vascular tissue and plays an important role in regulating VASCULAR SMOOTH MUSCLE contraction.
| Descriptor ID |
D054706
|
| MeSH Number(s) |
D08.811.277.352.640.150.500 D08.811.277.352.640.155.500 D12.644.360.008.500 D12.644.360.009.500 D12.776.476.008.500 D12.776.476.009.500
|
| Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 5- Cyclic Nucleotide Phosphodiesterases, Type 5
- Phosphodiesterase 5A, cGMP-Specific
- Phosphodiesterase 5A, cGMP Specific
- cGMP-Specific Phosphodiesterase 5A
- Phosphodiesterase 5A
- Phosphodiesterase Type 5
- Type 5, Phosphodiesterase
- Phosphodiesterase 5
- Phosphodiesterase-5
- Phosphodiesterase V
- cGMP-Binding, cGMP-Specific 3',5'-cyclic Nucleotide Phosphodiesterase
- PDE5 Phosphodiesterases
- Phosphodiesterases, PDE5
- Phosphodiesterase Type V
- Type V, Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 5".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Hydrolases [D08.811.277]
- Esterases [D08.811.277.352]
- Phosphoric Diester Hydrolases [D08.811.277.352.640]
- 3',5'-Cyclic-AMP Phosphodiesterases [D08.811.277.352.640.150]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.150.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D08.811.277.352.640.155]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.155.500]
- Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
- Intracellular Signaling Peptides and Proteins [D12.644.360]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.644.360.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.644.360.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.009.500]
- Proteins [D12.776]
- Intracellular Signaling Peptides and Proteins [D12.776.476]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.776.476.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.776.476.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.009.500]
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 5".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in Profiles.
-
Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials. Clin J Am Soc Nephrol. 2010 Jun; 5(6):985-95.
-
Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009 Mar; 6 Suppl 3:234-8.
-
Sustained normalization of high blood pressure in spontaneously hypertensive rats by implanted hemin pump. Hypertension. 2006 Oct; 48(4):685-92.
-
Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 2005 Oct; 140(4):707-8.
-
Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol. 2005 Jan; 38(1):175-84.
-
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 15; 21(18):3454-61.